Jianxiang Wang, Dr
Institute of Hematology & Blood Diseases Hospital, China
9
9
3
N/A
0
9
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+11 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (9)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Jorge E Cortes, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Guillermo Garcia-Manero, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Beata Holkova, MD
Massey Cancer Center
Shared therapeutic areas:
Brigitte C Widemann, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Jae Park, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Areej El-Jawahri, MD
Massachusetts General Hospital
Shared therapeutic areas:
Jorge Cortes, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Qifa Liu
Nanfang Hospital, Southern Medical University
Shared therapeutic areas:
Worked with same sponsors:
Courtney DiNardo, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Mary Horowitz, MD
Center for International Blood and Marrow Transplant Research
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (9)
Showing 9 of 9 trials
Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML
Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients
Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML
All 9 trials loaded